AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9715356 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (4 doses of intranasal cocaine 1 mg/kg every 30 min)
Number of subjects: 0
Study 9715356 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (4 doses of oral alcohol 1 g/kg)
Number of subjects: 0
Study 9715356 — intervention group
Group type: COMPARATOR
Intervention: Cocaine placebo (4 doses of placebo cocaine)
Number of subjects: 0
Study 9715356 — intervention group
Group type: COMPARATOR
Intervention: Alcohol placebo (4 doses of placebo alcohol)
Number of subjects: 0
Study 9280322 — intervention group
Group type: EXPERIMENTAL
Intervention: First protocol (2 units of fresh-frozen plasma and one buffy coat-poor RBC concentrate)
Number of subjects: 60
Study 9280322 — intervention group
Group type: EXPERIMENTAL
Intervention: Second protocol (additional in-line filtration of RBC)
Number of subjects: 60
Study 9280322 — intervention group
Group type: EXPERIMENTAL
Intervention: Third protocol (additional platelet concentrate recovery from buffy coat)
Number of subjects: 60
Study 1945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy for 24 hours postoperatively
Number of subjects: 100
Study 1945511 — intervention group
Group type: COMPARATOR
Intervention: No cold therapy
Number of subjects: 100
Study 7139705 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous insertion of intra-aortic balloon assist
Number of subjects: 53
Study 7139705 — intervention group
Group type: COMPARATOR
Intervention: Surgical insertion of intra-aortic balloon assist
Number of subjects: 53
Study 29959661 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of mothers diagnosed with major depression
Number of subjects: 132
Study 29959661 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison mothers
Number of subjects: 132
Study 30235685 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-Circle Post Standing Qigong (TCPSQ) intervention for 10 weeks
Number of subjects: 80
Study 30235685 — intervention group
Group type: COMPARATOR
Intervention: Unaltered lifestyle control group
Number of subjects: 80
Study 27072903 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative autologous stem cell transplant (ASCT)
Number of subjects: 198
Study 27072903 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone)
Number of subjects: 198
Study 24794512 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on Brodmann Area 9
Number of subjects: 15
Study 24794512 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on Brodmann Area 46
Number of subjects: 15
Study 22639289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 82; glucose, 80‐140 mg/dl)
Number of subjects: 165
Study 22639289 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (CGC; n = 83; glucose, 180‐200 mg/dl)
Number of subjects: 165
Study 20053938 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) including folic acid and 30 mg iron
Number of subjects: 4436
Study 20053938 — intervention group
Group type: COMPARATOR
Intervention: Folic acid and 30 mg iron (Fe30Fol)
Number of subjects: 4436
Study 20053938 — intervention group
Group type: COMPARATOR
Intervention: Usual food supplementation
Number of subjects: 4436
Study 20053938 — intervention group
Group type: EXPERIMENTAL
Intervention: Early food supplementation
Number of subjects: 4436
Study 18844462 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/r 600/100 mg twice daily
Number of subjects: 255
Study 18844462 — intervention group
Group type: COMPARATOR
Intervention: Control protease inhibitors (CPI(s))
Number of subjects: 255
Study 16496606 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CDGD
Number of subjects: 20
Study 16496606 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 20
Study 12195169 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different hearing aid circuits
Number of subjects: 360
Study 9924278 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal (standard energy content)
Number of subjects: 9
Study 9924278 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal (doubled energy content)
Number of subjects: 9
Study 9924278 — intervention group
Group type: COMPARATOR
Intervention: Fasting trial
Number of subjects: 9
Study 8171949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and vecuronium
Number of subjects: 60
Study 8171949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotics (etomidate, midazolam, propofol)
Number of subjects: 60
Study 8171949 — intervention group
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 60
Study 8171949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 60
Study 8171949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotics
Number of subjects: 60
Study 8171949 — intervention group
Group type: EXPERIMENTAL
Intervention: Post intubation period
Number of subjects: 60
Study 8171949 — intervention group
Group type: COMPARATOR
Intervention: Various hypnotics
Number of subjects: 60
Study 2965125 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 12
Study 2965125 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 12
Study 30273277 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) intervention
Number of subjects: 10
Study 27401514 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based symptom management (TSM) consisting of cognitive-behavioral and emotion-focused therapy
Number of subjects: 106
Study 27401514 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based symptom management (TSM)
Number of subjects: 106
Study 27401514 — intervention group
Group type: COMPARATOR
Intervention: Education/support condition
Number of subjects: 106
Study 25146070 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa adjuvant therapy
Number of subjects: 128
Study 25146070 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study 22741257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrounding needling of electroacupuncture and hot compress of Chinese medicine
Number of subjects: 86
Study 22741257 — intervention group
Group type: COMPARATOR
Intervention: Conventional needling method and local cupping
Number of subjects: 86
Study 19783466 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Astigmatism (AOfA)
Number of subjects: 14
Study 19783466 — intervention group
Group type: EXPERIMENTAL
Intervention: Purevision Toric (PVT)
Number of subjects: 14
Study 19783466 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix for Astigmatism (AOT)
Number of subjects: 14
Study 19783466 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear Toric (PCT)
Number of subjects: 14
Study 19027437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 155
Study 19027437 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMR)
Number of subjects: 155
Study 19027437 — intervention group
Group type: COMPARATOR
Intervention: Control (sham therapy or wait-list)
Number of subjects: 155
Study 16050413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 0
Study 16050413 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcimimetics
Number of subjects: 0
Study 16050413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments with selective drugs
Number of subjects: 0
Study 12871555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C treatment (1 g day‐1 for 5 days)
Number of subjects: 61
Study 10591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract (1050 mg, 350 mg three times daily)
Number of subjects: 263
Study 10591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg, 50 mg, 25 mg, and 25 mg daily)
Number of subjects: 263
Study 10591711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 10591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract
Number of subjects: 263
Study 10591711 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 263
Study 8910180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg
Number of subjects: 135
Study 8910180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 135
Study 8910180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg
Number of subjects: 135
Study 8910180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 135
Study 8910180 — intervention group
Group type: COMPARATOR
Intervention: Control (no lidocaine)
Number of subjects: 135
Study 1283888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (300 mg/day)
Number of subjects: 44
Study 1283888 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (300 mg/day)
Number of subjects: 44
Study 6371627 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan and 5‐fluorouracil daily for four days, repeated every four weeks with megace daily for eight weeks
Number of subjects: 358
Study 6371627 — intervention group
Group type: EXPERIMENTAL
Intervention: adriamycin, 5‐fluorouracil, and cyclophosphamide, intravenous bolus every 21 days with megace daily for eight weeks
Number of subjects: 358
Study 6371627 — intervention group
Group type: COMPARATOR
Intervention: Control group (63 patients with known cardiac disease assigned to regimen 1)
Number of subjects: 358
Study 30882856 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 30235437 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2
Number of subjects: 33
Study 30235437 — intervention group
Group type: COMPARATOR
Intervention: O2
Number of subjects: 33
Study 27329612 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml of fructose beverage
Number of subjects: 41
Study 27329612 — intervention group
Group type: COMPARATOR
Intervention: 600 ml of glucose beverage (control)
Number of subjects: 41
Study 27329612 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml of soft drink
Number of subjects: 41
Study 27329612 — intervention group
Group type: EXPERIMENTAL
Intervention: 355 ml of soft drink
Number of subjects: 41
Study 25007689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg plus 3 ml of 0.5% hyperbaric bupivacaine (Group BF)
Number of subjects: 186
Study 25007689 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus 3 ml of 0.5% hyperbaric bupivacaine (Group BS)
Number of subjects: 186
Study 25007689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group BT)
Number of subjects: 186
Study 22289106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 30
Study 22289106 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 30
Study 20466294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 240
Study 20466294 — intervention group
Group type: COMPARATOR
Intervention: PGE(2)
Number of subjects: 240
Study 17389213 — intervention group
Group type: COMPARATOR
Intervention: Stented bioprostheses (Carpentier‐Edwards Perimount [CEP])
Number of subjects: 68
Study 17389213 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless bioprostheses (Toronto SPV)
Number of subjects: 68
Study 17389213 — intervention group
Group type: COMPARATOR
Intervention: Stentless bioprostheses (Shelhigh Super Stentless)
Number of subjects: 68
Study 16218010 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative intervention using the natural environment
Number of subjects: 32
Study 11863352 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 19
Study 11863352 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 19
Study 10418894 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneously administered influenza and pneumococcal vaccines
Number of subjects: 26925
Study 10418894 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine alone
Number of subjects: 26925
Study 7594124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ca group (1,400 mg Ca per day)
Number of subjects: 11
Study 7594124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Ca group (400 mg Ca per day)
Number of subjects: 11
Study 2141886 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 10
Study 2141886 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 10
Study 6456202 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 130
Study 6456202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 31412087 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant BGL2 (rBGL2ur) antigen
Number of subjects: 90
Study 31412087 — intervention group
Group type: COMPARATOR
Intervention: Proprietary MiraVista Diagnostic (MVD) IgM
Number of subjects: 90
Study 31412087 — intervention group
Group type: COMPARATOR
Intervention: ID-TP assay using non-concentrated patient sera
Number of subjects: 90
Study 28619020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-year peer tutoring (CYPT)
Number of subjects: 116
Study 28619020 — intervention group
Group type: COMPARATOR
Intervention: Faculty-led training (FLT)
Number of subjects: 116
Study 23800161 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg injection
Number of subjects: 20
Study 23800161 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg infusion every 12 h
Number of subjects: 20
Study 23800161 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg infusion followed by continuous infusion at 8 mg/h
Number of subjects: 20
Study 23800161 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg infusion followed by continuous infusion at 4 or 8 mg/h
Number of subjects: 20
Study 23800161 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion
Number of subjects: 20
Study 21670453 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (180 μg/kg) administered before chemoradiotherapy and once weekly for 7 weeks
Number of subjects: 188
Study 21670453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 19194993 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (CS training)
Number of subjects: 89
Study 19194993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CS training)
Number of subjects: 89
Study 17023233 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol IR (Immediate-Release)
Number of subjects: 0
Study 17023233 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol CR (Controlled-Release)
Number of subjects: 0
Study 17023233 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol IR and Carvedilol CR
Number of subjects: 0
Study 15250016 — intervention group
Group type: COMPARATOR
Intervention: Cefepime monotherapy
Number of subjects: 189
Study 15250016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/amikacin combination (dual) therapy
Number of subjects: 189
Study 11745911 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid tablets administered while fasting
Number of subjects: 0
Study 11745911 — intervention group
Group type: COMPARATOR
Intervention: Linezolid tablets administered after a high-fat meal
Number of subjects: 0
Study 11745911 — intervention group
Group type: EXPERIMENTAL
Intervention: 375-mg oral dose of linezolid (tablets) while fasting
Number of subjects: 0
Study 11745911 — intervention group
Group type: COMPARATOR
Intervention: 375-mg intravenous linezolid solution
Number of subjects: 0
Study 9417761 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of rhenium‐186 combined with triamcinolonhexacetonid (group 1)
Number of subjects: 228
Study 9417761 — intervention group
Group type: COMPARATOR
Intervention: Injection of triamcinolonhexacetonid alone (group 2)
Number of subjects: 228
Study 9417761 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of erbium‐169 combined with triamcinolonhexacetonid (group 3)
Number of subjects: 228
Study 9417761 — intervention group
Group type: COMPARATOR
Intervention: Injection of triamcinolonhexacetonid alone (group 4)
Number of subjects: 228
Study 8518353 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (dietary advice)
Number of subjects: 0
Study 8518353 — intervention group
Group type: COMPARATOR
Intervention: Diet B (low calorie daily menus)
Number of subjects: 0
Study 2979677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 10
Study 2979677 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 31122843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB) administered preoperatively
Number of subjects: 60
Study 31122843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 29960767 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 minitablets
Number of subjects: 372
Study 29960767 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 minitablets
Number of subjects: 372
Study 29960767 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 minitablets
Number of subjects: 372
Study 29960767 — intervention group
Group type: COMPARATOR
Intervention: 5 mL syrup
Number of subjects: 372
Study 29960767 — intervention group
Group type: COMPARATOR
Intervention: 10 mL syrup
Number of subjects: 372
Study 26929280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapro mesh (pore size 3-4 mm)
Number of subjects: 128
Study 26929280 — intervention group
Group type: COMPARATOR
Intervention: Optilene LP mesh (pore size 1 mm)
Number of subjects: 128
Study 25222607 — intervention group
Group type: EXPERIMENTAL
Intervention: Val158 variant during medication and placebo treatment
Number of subjects: 62
Study 25222607 — intervention group
Group type: EXPERIMENTAL
Intervention: Val158/Val158 carriers
Number of subjects: 62
Study 23176879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg or 20 mg)
Number of subjects: 13
Study 23176879 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (5 mg nebulized)
Number of subjects: 13
Study 23176879 — intervention group
Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 13
Study 19836153 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in 20 twice‐daily fractions (Arm A)
Number of subjects: 113
Study 19836153 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in four daily fractions (Arm B)
Number of subjects: 113
Study 18456678 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 50
Study 18456678 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 50
Study 16958184 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization before consent
Number of subjects: 0
Study 16958184 — intervention group
Group type: COMPARATOR
Intervention: Standard consent process
Number of subjects: 0
Study 14871033 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (V group, n = 36)
Number of subjects: 73
Study 14871033 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (A group, n = 37)
Number of subjects: 73
Study 14871033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 10976537 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg/day administered on days 1, 3, and 5 in weeks 2-6 of radiotherapy
Number of subjects: 20
Study 10976537 — intervention group
Group type: COMPARATOR
Intervention: Accelerated hyperfractionated radiotherapy (1.6 Gy b.i.d., total dose 67.2 Gy in six weeks with a two-week split) and concomitant chemotherapy (cisplatin, 20 mg/m2/day, days 1-5 by continuous intravenous infusion)
Number of subjects: 20
Study 8922358 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular hyperfiltration (GFR >135 ml x min(‐1) x 1.73 m(‐2))
Number of subjects: 50
Study 8922358 — intervention group
Group type: COMPARATOR
Intervention: Glomerular normofiltration (GFR 83‐135 ml x min(‐1) x 1.73 m(‐2))
Number of subjects: 50
Study 8922358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 1319875 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70 (antacid)
Number of subjects: 12
Study 6375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 19
Study 6375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 30 mg
Number of subjects: 19
Study 6375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 40 mg
Number of subjects: 19
Study 6375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (all doses)
Number of subjects: 19
Study 31604480 — intervention group
Group type: COMPARATOR
Intervention: Once Daily (OD) screening
Number of subjects: 760
Study 31604480 — intervention group
Group type: EXPERIMENTAL
Intervention: At least Twice Daily (ALTD) screening
Number of subjects: 760
Study 31604480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support (PS) + Positive End‐Expiratory Pressure (PEEP) SBT technique
Number of subjects: 760
Study 31604480 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece SBT technique
Number of subjects: 760
Study 28599588 — intervention group
Group type: EXPERIMENTAL
Intervention: Happier Meals vicarious learning video
Number of subjects: 50
Study 28599588 — intervention group
Group type: COMPARATOR
Intervention: Control video about education
Number of subjects: 50
Study 27112434 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing a soft ball
Number of subjects: 120
Study 27112434 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 120
Study 27112434 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction cards
Number of subjects: 120
Study 24439465 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS plus fluoroscopy
Number of subjects: 145
Study 24439465 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy alone
Number of subjects: 145
Study 22542645 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise informed consent form
Number of subjects: 111
Study 22542645 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent form
Number of subjects: 111
Study 19562446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera cream
Number of subjects: 30